NOV 17, 202663 MINS READ
Creatine phosphate (phosphocreatine, PCr) constitutes a critical energy buffer in skeletal and cardiac muscle, functioning within the phosphagen system to rapidly regenerate adenosine triphosphate (ATP) from adenosine diphosphate (ADP) via the creatine kinase (CK) reaction 1. During the initial 5–10 seconds of high-intensity muscular contraction, intramuscular ATP stores are depleted, and PCr donates its high-energy phosphate group to ADP, sustaining ATP availability before glycolytic and oxidative pathways are fully activated 5. Approximately 65% of total muscle creatine exists as phosphocreatine under resting conditions 14, and this pool can drop by nearly 50% within six seconds of maximal exercise 14. The CK reaction is reversible and operates at diffusion-limited rates, ensuring that ATP concentration remains relatively stable even as PCr is consumed 11.
The importance of creatine phosphate extends beyond immediate energy provision. It also plays a role in:
Muscle fatigue onset is commonly associated with PCr depletion, as the capacity for rapid ATP regeneration diminishes once phosphocreatine stores are exhausted 16. Consequently, strategies to increase muscle PCr content—either through exogenous supplementation or by enhancing endogenous synthesis—have been pursued to delay fatigue and improve performance.
While creatine (Cr) is the most widely used dietary supplement for increasing muscle PCr stores, direct administration of creatine phosphate presents significant challenges. Creatine supplementation at doses of 20 g/day or higher can elevate intramuscular creatine and PCr concentrations by approximately 20–30% 1,3, with only about 25% of ingested creatine being phosphorylated to PCr in vivo 1,2. However, high-dose creatine regimens (>20 g/day) are associated with adverse effects, particularly renal stress and gastrointestinal discomfort 1,3.
Creatine phosphate itself is highly unstable in aqueous solution and gastric acid, rendering oral administration impractical 1,2,3. To circumvent these limitations, researchers have developed:
Comparative studies indicate that intravenous creatine phosphate can improve exercise tolerance during prolonged submaximal activity, whereas oral creatine supplementation primarily benefits intermittent, supramaximal efforts 11,13. The choice of supplementation strategy should therefore be tailored to the specific metabolic demands and duration of the target activity.
Emerging evidence supports the use of multi-component formulations that combine creatine or creatinol-phosphate with other metabolic modulators to achieve synergistic effects on muscle performance and fatigue resistance.
A patented composition combining L-carnitine (or alkanoyl L-carnitines such as acetyl-, propionyl-, or isovaleryl-L-carnitine) with creatinol-phosphate has demonstrated potent synergistic efficacy in preventing and treating muscular energy deficiencies, asthenia, and muscle fatigue 1,2,3,6. L-carnitine facilitates mitochondrial fatty acid oxidation, thereby sparing glycogen and reducing lactate accumulation during prolonged exercise 1. When co-administered with creatinol-phosphate, this combination:
Recommended dosing for creatinol-phosphate in these formulations ranges from 0.5 to 5 g per day, with an optimal dose of approximately 1.5 g twice daily 7,8,9. L-carnitine is typically administered at 1–3 g/day 1,2,3.
Another synergistic formulation combines creatine with taurine and a phosphate source (e.g., inorganic phosphate salts or phosphorylated carbohydrates) 14. Taurine, a sulfur-containing amino acid, modulates calcium homeostasis in muscle cells, enhances mitochondrial function, and exhibits antioxidant properties 14. The addition of exogenous phosphate accelerates PCr resynthesis during recovery intervals, thereby improving performance in repeated high-intensity bouts 14. This combination has been shown to:
Typical dosing includes 3–5 g creatine, 1–2 g taurine, and 0.5–1 g phosphate per day 14.
A recent formulation pairs creatine with oleuropein (or its metabolites, such as hydroxytyrosol), a polyphenolic compound derived from olive leaves 12. This combination targets mitochondrial calcium uptake and utilization in muscle cells, leading to:
The proposed mechanism involves oleuropein-mediated upregulation of mitochondrial calcium uniporter activity, which synergizes with creatine's role in ATP-PCr cycling 12.
Muscle fatigue is a multifactorial phenomenon involving depletion of energy substrates, accumulation of metabolic byproducts (e.g., inorganic phosphate, H⁺, ADP), and impaired excitation-contraction coupling 5,11. Creatine phosphate and its analogs address several of these mechanisms:
The CK-catalyzed transfer of phosphate from PCr to ADP is the fastest route for ATP resynthesis, operating on a millisecond timescale 5,11. By maintaining ATP/ADP ratios above critical thresholds, PCr delays the activation of AMP-activated protein kinase (AMPK) and other fatigue-signaling pathways 11.
During anaerobic glycolysis, lactate and H⁺ accumulate, lowering intracellular pH and inhibiting glycolytic enzymes and contractile proteins 1,7. The net reaction of PCr hydrolysis consumes one proton per ATP regenerated, thereby attenuating acidosis 1,7. Creatinol-phosphate has been specifically noted for its ability to act as a hydrogen ion (H⁺) blocker, further stabilizing pH during high-intensity exercise 7,8,9.
Creatinol-phosphate exhibits membrane-protective properties, reducing lipid peroxidation and ROS-mediated damage to muscle fibers 1,3,6. This effect is particularly relevant during eccentric exercise or ischemia-reperfusion, where oxidative stress is elevated 1,6. By preserving sarcolemmal integrity, creatinol-phosphate may reduce muscle soreness and accelerate recovery 15.
Emerging data suggest that creatine and oleuropein co-administration enhances mitochondrial calcium uptake, which is essential for activating oxidative phosphorylation and matching ATP supply to demand 12. Improved calcium handling may also reduce the energetic cost of calcium cycling by the sarcoplasmic reticulum, thereby conserving ATP 12.
Creatine supplementation is well-established for improving performance in sports requiring repeated high-intensity efforts (e.g., sprinting, weightlifting, team sports) 13,14,16. Meta-analyses indicate that creatine loading (20 g/day for 5–7 days, followed by 3–5 g/day maintenance) increases lean body mass by 1–2 kg, enhances maximal strength by 5–15%, and improves sprint performance by 1–5% 13. Creatinol-phosphate and alkaline creatine formulations may extend these benefits to endurance athletes by delaying PCr depletion and reducing perceived exertion during prolonged submaximal exercise 4,5,11.
Age-related declines in muscle mass and strength (sarcopenia) are associated with reduced muscle creatine and PCr content 1,7. Supplementation with creatine or creatinol-phosphate has been shown to increase muscle strength in elderly populations, reduce asthenia, and improve functional mobility 1,3,7. The combination of creatine with oleuropein is particularly promising for frail or pre-frail individuals, as it addresses both energetic and mitochondrial deficits 12.
Creatinol-phosphate administration accelerates recovery of muscle strength and reduces fatigue in convalescent patients, including those recovering from myocardial infarction or major surgery 1,3,10. Intravenous phosphocreatine has been used clinically to restore cardiac efficiency and improve exercise tolerance in post-infarct patients 1,10.
Creatine and its derivatives are effective for preventing or alleviating non-pathological muscle impairments such as delayed-onset muscle soreness (DOMS), muscle weakness, and tension 15. Recommended single doses range from 10 mg to 10 g, with daily intakes of 30 mg to 30 g depending on body weight and activity level 15.
Creatine monohydrate is widely available as a dietary supplement and is not subject to prescription regulation in most jurisdictions. Creatinol-phosphate is marketed in some countries as a pharmaceutical agent (e.g., for cardiac indications) and may require medical oversight 1,10. Consumers should select products certified by third-party testing organizations (e.g., NSF Certified for Sport, Informed-Choice) to ensure purity and absence of banned substances.
Rodent models of muscle fatigue and performance have been instrumental in elucidating the mechanisms of creatine phosphate action. Key models include:
Clinical and field-based assessments of muscle strength and fatigue include:
Emerging research indicates that genetic variation in creatine kinase isoforms, creatine transporter (SLC6A8), and guanidinoacetate methyltransferase (GAMT) may influence individual responses to creatine supplementation 13. Personalized dosing strategies based on genotype could optimize efficacy and minimize
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| SIGMA-TAU HEALTHSCIENCE S.P.A. | Prevention and treatment of muscular energy deficiencies, asthenia, muscle fatigue, heart fatigue, post-infarct recovery, and enhancement of athletic performance in both clinical and sports populations. | Creatinol-Phosphate + L-Carnitine Formulation | Synergistic combination enhances ATP synthesis and phosphocreatine resynthesis, stabilizes cell membranes against ROS-induced damage, increases muscular strength in elderly populations, and restores cardiac efficiency post-infarction at low doses (0.5-5g/day creatinol-phosphate). |
| XENOPORT INC. | Treatment of ischemia, heart failure, neurodegenerative disorders, muscle fatigue during high-intensity and endurance exercise, and enhancement of muscle strength in clinical and athletic settings. | Creatine Phosphate Prodrugs | Membrane-permeable prodrugs enable intracellular creatine phosphate delivery, bypassing endogenous phosphorylation requirements, improving exercise tolerance during prolonged submaximal exercise, and maintaining ATP/ADP ratios to delay fatigue-signaling pathways. |
| Golini Jeffrey M. | Endurance sports and prolonged submaximal exercise activities requiring delayed fatigue onset and enhanced exercise tolerance beyond explosive energy demands. | Alkaline Creatine Formulation | Buffered creatine preparation (pH 7-14) enhances chemical stability, reduces degradation to creatinine, and improves endurance performance during sustained submaximal exercise lasting 90 seconds to 3 hours. |
| SOCIÉTÉ DES PRODUITS NESTLÉ S.A. | Aging populations, elderly subjects, sarcopenic individuals, frail or pre-frail subjects, physical rehabilitation, and treatment of muscle disorders linked to calcium depletion or mitochondrial deficits. | Creatine + Oleuropein Combination | Synergistic formulation improves mitochondrial calcium uptake and utilization, enhances mitochondrial energy production, increases muscle functionality and lean mass, decreases muscle fatigue, and provides therapeutic benefits in sarcopenia and frailty. |
| NEW CELL FORMULATIONS LTD. | High-intensity repeated exercise bouts, athletic performance enhancement, muscle mass building, and accelerated recovery in sports requiring rapid ATP regeneration and repeated maximal efforts. | Creatine + Taurine + Phosphate Formulation | Combination increases creatine uptake and retention in skeletal muscle, accelerates phosphocreatine resynthesis during recovery intervals, augments muscle mass and strength, and enhances exercise capacity with improved post-exercise recovery. |